Professor Reinhard Dummer is Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently he is heading of the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Professor Dummer began his medical education in hematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich in 1992. He is Board Certified in allergology, clinical immunology, dermatology and dermatopathology.

Professor Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. He has published more than 741 papers with a cumulative impact factor of more than 6372. He was past-president of the Melanoma Project Group of the Swiss Institute for Applied Cancer Research since 1999 -2016, is a member of German National Academy of Sciences (Leopoldina) and is past board member of the Society for Melanoma Research and past President of the International Society for Cutaneous Lymphomas. He is a founding and board member of the European Association of Dermato-Oncology (EADO), ESMO, URPP and past President of the European Society for Dermatological Research (ESDR).

In the last 20 years, he has developed a leading skin cancer center. This center offers best medical care, a network of clinical trials reaching from phase I to phase III. His contributions are acknowledge in many publications in outstanding journals such as New England Journal of Medicine, Lancet, Lancet Oncology, Press etc. Locally he is intensify cooperation with basic research group at the University and the federal University (ETH). This has resulted in translation work improving our understanding of cutaneous malignancies.

Dr. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. His research focuses on the pathogenesis and treatment of liver fibrosis. Dr. Friedman began his research career at UCSF, where he identified hepatic stellate cells as the principal effectors of liver fibrosis. In his current role at Mount Sinai, he seeks to accelerate discovery and translate scientific advances into new treatments for human disease. Dr. Friedman has participated in center programs at NIDDK and NIAAA and currently co-leads a program on liver cancer funded by NCI.

Dr. Harrison earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology. Dr. Harrison served as a Professor of Medicine at the Uniformed Services University of the Health Sciences and is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is a past Associate Editor for Hepatology and is currently an Associate Editor for Alimentary Pharmacology and Therapeutics. He is a peer-reviewer for over 20 medical journals and internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 170 peer reviewed publications in these fields. Dr. Harrison most recently served as a Colonel in the United States Army. Retiring in 2016, he concluded 20 years of dedicated service to his country. During his army tenure, he served as the Director of Graduate Medical Education at Brooke Army Medical Center, Associate Dean for the San Antonio Uniformed Services Health Education Consortium and Gastroenterology Consultant to the Army Surgeon General. Currently, Dr. Harrison serves as the Medical Director for Pinnacle Clinical Research.

Jerrold M. Olefsky, MD, is Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine. His work has been instrumental in defining the basic genetic and cellular mechanisms responsible for the pathogenesis of Type II Diabetes, metabolic syndrome, and other diseases. Dr. Olefsky is a member of the Institute of Medicine and was the 1998 recipient of the American Diabetes Association’s Banting Medal for Scientific Achievement.

R. Balfour Sartor, MD, is the Midgette Distinguished Professor of Medicine, Microbiology & Immunology, and Co-Director of the UNC Multidisciplinary Center for IBD Research and Treatment. He is a nationally and internationally recognized authority on mucosal immunology and inflammatory bowel disease. His research focuses on better defining mechanisms of chronic intestinal inflammation, mucosal homeostasis and identifying new areas for therapeutic intervention for patients with inflammatory bowel disease. His lab investigates the ability of specific components of the intestinal microbiota to induce chronic T-cell mediated inflammation in genetically susceptible hosts as compared to a protective mucosal immune response in normal hosts. Additional studies explore the ability for dietary products to modify the composition and function of intestinal microbiota. Recent work has extended these microbial-host interactions to analysis of human samples, comparing healthy subjects to both Crohn's disease and ulcerative colitis patients. Dr. Sator is currently the Chief Medial Advisor to the Crohn's and Colitis Foundation of America (CCFA).

Academic Appointments
Associate Professor, Microbiology & Immunology
Member, Bio-X
Faculty Fellow, Stanford ChEM-H

Honors & Awards
NIH Director's New Innovator Award, NIH (2009)
Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease Award, Burroughs Wellcome Fund (2011)
NIH Director's Pioneer Award, NIH (2017)

Professional Education
BS, UC Davis, Biochemistry (1996)
PhD, UC San Diego, Biomedical Sciences (2003)

Dr. Alan Venook is the Madden Family Distinguished Professor of Medical Oncology and Translational Research and the Shorenstein Associate Director for Program Development at the Helen Diller Family Comprehensive Cancer Center at UCSF. He was the founding Chairman of the NCI’s Hepatobiliary Task Force and chaired the GI Committee of the Alliance for Clinical Trials in Oncology from 2010-15. He is presently Vice-Chair of the NCCN Colorectal Cancer Guideline Panel.